BBC
Virtus LifeSci Biotech Clinical Trials ETF
Price Chart
Latest Quote
$42.87
+1.81 (+4.40%)
Current Price
| Previous Close | $41.06 |
| Open | $41.20 |
| Day High | $42.87 |
| Day Low | $42.02 |
| Volume | 125,720 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.42% |
| Net Assets | $43.83M |
| Expense Ratio | 0.65% |
| Category | Health |
| Fund Family | Virtus |
| Net Asset Value | $41.18 |
| Premium/Discount | 4.11% |
| Quarterly Dividend Yield | 1.42% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 41.46 |
| ATR | nan |
| Rel Volume | 3.47 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 125,720 |
| 2026-10-26 | $41.06 | 6,000 |
| 2026-10-23 | $41.22 | 12,700 |
| 2026-10-22 | $42.13 | 30,900 |
| 2026-10-21 | $42.42 | 9,000 |
| 2026-10-20 | $42.61 | 36,200 |
| 2026-10-19 | $40.82 | 86,000 |
| 2026-10-16 | $39.12 | 85,400 |
| 2026-10-15 | $41.16 | 45,000 |
| 2026-10-14 | $40.15 | 86,400 |
| 2026-10-13 | $40.64 | 52,900 |
| 2026-10-12 | $43.06 | 10,300 |
| 2026-10-09 | $44.15 | 5,300 |
| 2026-10-08 | $43.24 | 14,200 |
| 2026-10-07 | $43.29 | 17,400 |
| 2026-10-06 | $43.26 | 27,900 |
| 2026-10-05 | $44.61 | 18,500 |
| 2026-10-02 | $44.56 | 9,000 |
| 2026-10-01 | $45.00 | 25,000 |
| 2026-09-30 | $46.29 | 20,200 |
| 2026-09-29 | $45.85 | 11,100 |
| 2026-09-28 | $46.12 | 23,000 |
About Virtus LifeSci Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
đ° Latest News
No news articles available at the moment. Check back later for updates on BBC.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.